Filtered By:
Condition: Atrial Fibrillation
Countries: Japan Health
This page shows you your search results in order of date. This is page number 20.
Order by Relevance | Date
Total 333 results found since Jan 2013.
Real-world outcomes of the Xarelto Post-Authorization Safety & Effectiveness Study in Japanese Patients with Atrial Fibrillation (XAPASS).
CONCLUSIONS: Real-world outcomes of the XAPASS showed incidence rates of major bleeding and thromboembolic events, suggesting that rivaroxaban is safe and effective in Japanese daily clinical practice (Clinicaltrials.gov: NCT01582737).
PMID: 30745002 [PubMed - as supplied by publisher]
Source: Journal of Cardiology - February 7, 2019 Category: Cardiology Authors: Ikeda T, Ogawa S, Kitazono T, Nakagawara J, Minematsu K, Miyamoto S, Murakawa Y, Takeichi M, Ohashi Y, Okayama Y, Sunaya T, Yamanaka S Tags: J Cardiol Source Type: research
Clinical Outcomes of Off-Label Dosing of Direct Oral Anticoagulant Therapy Among Japanese Patients With Atrial Fibrillation Identified From the SAKURA AF Registry.
CONCLUSIONS: Clinical outcomes were not worse for under-dose than for standard-dose users among patients with different backgrounds. Over-dose users, however, were at higher risk for all clinical events and required careful follow-up. Further studies are needed to clarify the safety and effectiveness of off-label DOAC dosing in Japan.
PMID: 30726797 [PubMed - as supplied by publisher]
Source: Circulation Journal - February 5, 2019 Category: Cardiology Authors: Murata N, Okumura Y, Yokoyama K, Matsumoto N, Tachibana E, Kuronuma K, Oiwa K, Matsumoto M, Kojima T, Hanada S, Nomoto K, Arima K, Takahashi F, Kotani T, Ikeya Y, Fukushima S, Itoh S, Kondo K, Chiku M, Ohno Y, Onikura M, Hirayama A, SAKURA AF Registry Inv Tags: Circ J Source Type: research
Effectiveness and safety of long-term dabigatran among patients with non-valvular atrial fibrillation in clinical practice: J-dabigatran surveillance.
CONCLUSIONS: The present results are indicative of the favorable benefit-risk profile of dabigatran in Japanese clinical practice. Dabigatran dose was not independently associated with thromboembolic and bleeding events in Japanese NVAF patients.
PMID: 30737182 [PubMed - as supplied by publisher]
Source: Journal of Cardiology - February 5, 2019 Category: Cardiology Authors: Inoue H, Uchiyama S, Atarashi H, Okumura K, Koretsune Y, Yasaka M, Yamashita T, Taniguchi A, Fukaya T, J-Dabigation Surveillance Investigators Tags: J Cardiol Source Type: research
Impact of atrial high-rate episodes on the risk of future stroke.
CONCLUSIONS: Embolic stroke events are common in Japanese patients with CIEDs. AF events lasting ≥30s and an enlarged left atrium are the risk factors of embolic stroke in this population.
PMID: 30728105 [PubMed - as supplied by publisher]
Source: Journal of Cardiology - February 3, 2019 Category: Cardiology Authors: Nakano M, Kondo Y, Nakano M, Kajiyama T, Hayashi T, Ito R, Takahira H, Kobayashi Y Tags: J Cardiol Source Type: research
Safety of Anticoagulant Therapy Including Direct Oral Anticoagulants in Patients With Acute Spontaneous Intracerebral Hemorrhage.
CONCLUSIONS: Anticoagulant therapy was conducted for approximately 90% of anticoagulation-indicated patients after a median of 7 days from ICH onset. The predominant anticoagulant medications were DOACs. Anticoagulant therapy started from the acute phase of ICH should be safe.
PMID: 30587698 [PubMed - as supplied by publisher]
Source: Circulation Journal - December 27, 2018 Category: Cardiology Authors: Sakamoto Y, Nito C, Nishiyama Y, Suda S, Matsumoto N, Aoki J, Shimoyama T, Kanamaru T, Suzuki K, Nishimura T, Mishina M, Kimura K Tags: Circ J Source Type: research
Risk Profile and 1-Year Outcome of Newly Diagnosed Atrial Fibrillation in Japan - Insights From GARFIELD-AF.
CONCLUSIONS: GARFIELD-AF continues to provide important information on the homogeneity and heterogeneity of baseline characteristics and treatment patterns in patients with newly diagnosed NVAF. This diversity reflects the differences in outcomes in Japan compared with the rest of the world.
PMID: 30518731 [PubMed - as supplied by publisher]
Source: Circulation Journal - December 4, 2018 Category: Cardiology Authors: Koretsune Y, Etoh T, Katsuda Y, Suetsugu T, Kumeda K, Sakuma I, Eshima K, Shibuya M, Ando SI, Yokota N, Goto S, Pieper KS, Allu J, Kakkar AK, GARFIELD-AF Investigators Tags: Circ J Source Type: research
Contemporary trend of reduced-dose non-vitamin K anticoagulants in Japanese patients with atrial fibrillation: A cross-sectional analysis of a multicenter outpatient registry.
CONCLUSIONS: Nearly half of the NOAC dose reductions in our registry were deemed "non-standardized," which were seen mostly in patients at significant risk for ischemic stroke. The physician's apprehension regarding excessive bleeding under NOAC use should be appropriately balanced with concern for an increased risk of embolic events.
PMID: 30487057 [PubMed - in process]
Source: Journal of Cardiology - December 1, 2018 Category: Cardiology Authors: Ono T, Ikemura N, Kimura T, Ueda I, Tanaka H, Tokuda H, Yajima N, Matsumura K, Suzuki M, Fukuda K, Kohsaka S, Takatsuki S Tags: J Cardiol Source Type: research
Current Status, Time Trends and Outcomes of Combination Therapy With Oral Anticoagulant and Antiplatelet Drug in Patients With Atrial Fibrillation - The Fushimi AF Registry.
CONCLUSIONS: In Japanese AF patients receiving OAC, the prevalence of combination therapy decreased, with the proportion of NOAC use increasing in 2011-2017. Many patients, however, received off-label NOAC under-dosing, especially in the combination therapy group. Patients with combination therapy had higher incidences of major bleeding as well as stroke/systemic embolism, compared with OAC monotherapy.
PMID: 30381701 [PubMed - as supplied by publisher]
Source: Circulation Journal - October 31, 2018 Category: Cardiology Authors: Masunaga N, Abe M, Ogawa H, Aono Y, Ikeda S, Doi K, An Y, Ishii M, Iguchi M, Esato M, Tsuji H, Wada H, Hasegawa K, Lip GYH, Akao M, Fushimi AF Registry Investigators Tags: Circ J Source Type: research
Percutaneous WATCHMAN Left Atrial Appendage Closure for Japanese Patients With Nonvalvular Atrial Fibrillation at Increased Risk of Thromboembolism - First Results From the SALUTE Trial.
CONCLUSIONS: The procedural safety and 6-month results from the SALUTE trial demonstrated that the LAA closure device was safe and effective, similar to the results of large-scale randomized clinical trials, and provides a novel perspective of LAA closure for Japanese patients with NVAF in need of an alternative to long-term oral-anticoagulation. (Trial Registration: clinicaltrials.gov Identifier NCT 03033134).
PMID: 30305484 [PubMed - as supplied by publisher]
Source: Circulation Journal - October 11, 2018 Category: Cardiology Authors: Aonuma K, Yamasaki H, Nakamura M, Ootomo T, Takayama M, Ando K, Hirao K, Morino Y, Hayashida K, Kusano K, Main ML, Saito S Tags: Circ J Source Type: research
Validation of Conventional Thromboembolic Risk Factors in a Korean Atrial Fibrillation Population - Suggestion for a Novel Scoring System, CHA2DS2-VAK.
CONCLUSIONS: Female sex was not associated with TE events in a Korean non-valvular AF population. The novel CHA2DS2-VAK scoring system, with substitution of CKD for female sex, might be more appropriate for the Korean population.
PMID: 30282848 [PubMed - as supplied by publisher]
Source: Circulation Journal - October 4, 2018 Category: Cardiology Authors: Cha MJ, Cho Y, Oh IY, Choi EK, Oh S Tags: Circ J Source Type: research
EdoxabaN Versus standard of care and theIr effectS on clinical outcomes in pAtients havinG undergonE Transcatheter Aortic Valve Implantation in Atrial Fibrillation—Rationale and design of the ENVISAGE-TAVI AF trial
Publication date: November 2018Source: American Heart Journal, Volume 205Author(s): Nicolas M. Van Mieghem, Martin Unverdorben, Marco Valgimigli, Roxana Mehran, Eric Boersma, Usman Baber, Christian Hengstenberg, Minggao Shi, Cathy Chen, Shigeru Saito, Roland Veltkamp, Pascal Vranckx, George D. DangasTranscatheter aortic valve implantation, also called transcatheter aortic valve replacement (TAVR), is the treatment of choice for patients with severe aortic stenosis and intermediate to high operative risk. A significant portion of TAVR patients have atrial fibrillation (AF) requiring chronic oral anticoagulation. In moderate...
Source: American Heart Journal - August 30, 2018 Category: Cardiology Source Type: research
Anticoagulants, Reperfusion Therapy, and Outcomes in Ischemic Stroke Patients With Non-Valvular Atrial Fibrillation - A Single-Center, 6-Year Experience of 546 Consecutive Patients.
CONCLUSIONS: Inappropriate anticoagulant use for stroke patients with NVAF did not decrease over time. An increase in reperfusion therapy was a strong factor in improved functional outcomes and mortality.
PMID: 30158346 [PubMed - as supplied by publisher]
Source: Circulation Journal - August 30, 2018 Category: Cardiology Authors: Suda S, Sakamoto Y, Okubo S, Aoki J, Shimoyama T, Kanamaru T, Suzuki K, Kutsuna A, Matsumoto N, Nito C, Nishiyama Y, Mishina M, Kimura K Tags: Circ J Source Type: research
Three-Year Clinical Outcomes Associated With Warfarin vs. Direct Oral Anticoagulant Use Among Japanese Patients With Atrial Fibrillation - Findings From the SAKURA AF Registry.
CONCLUSIONS: A high follow-up rate allowed us to obtain reliable data on the status of OAC use and therapeutic outcomes among AF patients in Japan. Warfarin and DOACs appear to yield equivalent 3-year stroke and all-cause mortality rates, but DOACs appear to reduce the risk of major bleeding.
PMID: 30078823 [PubMed - as supplied by publisher]
Source: Circulation Journal - August 4, 2018 Category: Cardiology Authors: Okumura Y, Yokoyama K, Matsumoto N, Tachibana E, Kuronuma K, Oiwa K, Matsumoto M, Kojima T, Hanada S, Nomoto K, Arima K, Takahashi F, Kotani T, Ikeya Y, Fukushima S, Itou S, Kondo K, Chiku M, Ohno Y, Onikura M, Hirayama A, SAKURA AF Registry Investigators Tags: Circ J Source Type: research
Patient-reported treatment satisfaction with rivaroxaban in Japanese non-valvular atrial fibrillation patients: an observational study.
CONCLUSIONS: Findings suggest treatment satisfaction may improve in Japanese NVAF patients after a switch from warfarin to rivaroxaban. Higher treatment satisfaction may translate into improved treatment adherence, which is critical for the long-term prevention of stroke.
PMID: 30067119 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - August 3, 2018 Category: Research Tags: Curr Med Res Opin Source Type: research
Primary and secondary prevention of stroke and systemic embolism with rivaroxaban in patients with non-valvular atrial fibrillation
AbstractThe EXPAND Study examined the real-world efficacy and safety of rivaroxaban for the prevention of stroke and systemic embolism (SE) in Japanese patients with non-valvular atrial fibrillation (NVAF). In this sub-analysis, we compared the differences in efficacy and safety between patients with and those without history of stroke or transient ischemic attack (TIA). This multicenter, prospective, non-interventional, observational, cohort study was conducted at 684 medical centers in Japan. A total of 7141 NVAF patients aged ≥ 20 years [mean age 71.6 ± 9.4 (SD) years] who were being or planned to be treate...
Source: Heart and Vessels - July 6, 2018 Category: Cardiology Source Type: research
